Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465863 | 0.82 | MAOB (0.53) | MAOAMAOBNPC1RAB9AATM | |
| SCHEMBL7044951 | 0.82 | XDH (0.56) | MAOAMAOBNPC1RAB9AATM | |
| SCHEMBL7046752 | 0.75 | CYP3A4 (0.62) | MAOANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2464626 | 0.74 | MAOA (0.53) | MAOANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL5748656 | 0.72 | XDH (0.58) | MAOAMAOBTDP1 | |
| SCHEMBL5747713 | 0.72 | XDH (0.55) | MAOAMAOBTDP1 | |
| SCHEMBL5748784 | 0.71 | XDH (0.58) | MAOAMAOBTDP1 | |
| SCHEMBL28675845 | 0.71 | XDH (0.66) | MAOAMAOBTDP1 | |
| SCHEMBL6893811 | 0.70 | MAOA (0.69) | MAOANPC1RAB9AKDM4ETDP1 | |
| SCHEMBL4914778 | 0.68 | MAOA (0.61) | MAOAMAOBNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4782337-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| US-6608089-B2 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2003-08-19 | — | — | US | claimed |
| EP-1212312-B1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA SPA (IT) | 2003-04-02 | — | — | EP | claimed |
| JP-2003508524-A | — | — | 2003-03-04 | — | — | JP | claimed |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2002-12-05 | — | — | US | claimed |
| EP-1212312-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001017985-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | claimed |
| US-6608089-B2 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2003-08-19 | — | — | US | disclosed |
| EP-1212312-B1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA SPA (IT) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
| EP-1212312-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017985-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | BRCA1, NCEH1, EZH1 | MAOA 3604/4885MAOB 3241/4885NPC1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.